Valerion starts VAL-1221 dosing in Phase I/II trial for Pompe disease

Valerion Therapeutics has started dosing patients in a Phase I/II clinical trial of VAL-1221 to treat patients suffering from late-onset Pompe disease.

Source: Drug Development Technology - July 12, 2017 Category: Pharmaceuticals Source Type: news